Predict Prostate Cancer

Prostate cancer remains a major public health problem, being one of the most prevalent cancers affecting men. This disease originates in the prostate gland and varies considerably in its aggressiveness: some forms progress slowly and may require little or no intervention, while others may progress rapidly and metastasize. Age is a primary risk factor; It frequently affects men over 65 years of age, with a higher incidence in black men, those with a family history, and people with obesity (1). Early-stage prostate cancer may present without symptoms, but more advanced disease can cause urinary difficulties, blood in the urine, erectile dysfunction, and pelvic discomfort (2).

Early detection and treatment are critical, and screening methods such as PSA testing and DRE are critical components of effectively managing the condition. Depending on the stage, treatments may include surgery, radiation, hormone therapy, or chemotherapy (3). Prostate cancer is the second most common cancer in men worldwide, and approximately 1 in 8 men are likely to be diagnosed. during his life (3)(4).

• Prostate cancer is a major public health issue and one of the most prevalent cancers in men, with varying levels of aggressiveness.
• Age, race, family history, and obesity are primary risk factors, with early-stage disease often presenting without symptoms but advanced stages causing urinary issues, blood in urine, erectile dysfunction, and pelvic discomfort.
• Prostate cancer is the second most common cancer in men globally, with about 1 in 8 men likely to be diagnosed in their lifetime; early detection through PSA testing and DRE is crucial for effective management.

"ProCare AI" is an assistant that streamlines risk assessment and provides up-to-date treatment recommendations, improving efficiency in prostate cancer management.

User person: Urologists, Oncologists, General Physician, Men's Health Specialists, Medical Researchers.

This assistant's training includes data from the Colombian National Cancer Institute's “Manual for Early Detection of Cancer Protherapy” (5), supplemented by the “Guidelines for the Early Detection of Prostate Cancer” by Carter et al. (6), and the clinical practice guidelines of the Ministry of Health and Social Protection of Colombia (7).